𝛼SK or Searchbullish
Hone Health: The $55M/year D2C Testosterone Startup
127 Views21 Feb 2024 08:00
TL;DR: In 2023, Hone Health hit $55M in annualized revenue selling direct-to-consumer testosterone, capitalizing on the government’s loosening of the rules around online prescription for controlled substances. Now, they're using their superior economics around LTV to cross-sell into more products. For more, check out our report and dataset on Hone Health...
What is covered in the Full Insight:
- Introduction
- Growth and Revenue
- Market Dynamics and Competition
- Operational and Regulatory Challenges
- Future Products and Expansion
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Hone Health: The $55M/year D2C Testosterone Startup21 Feb 2024
x